Non-Muscle Invasive Bladder Neoplasms Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Non-Muscle Invasive Bladder Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC150 enrolled1 locationNCT07309445
Recruiting
Phase 3

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled104 locationsNCT06919965
Recruiting
Phase 1Phase 2

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC235 enrolled59 locationsNCT05316155
Recruiting
Phase 3

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC641 enrolled193 locationsNCT06319820
Recruiting
Phase 2

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Urinary Bladder NeoplasmsCarcinoma In SituNon-Muscle Invasive Bladder Neoplasms
Merck Sharp & Dohme LLC308 enrolled89 locationsNCT06833073
Recruiting
Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+4 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder CancerBladder NeoplasmNon Muscle Invasive Bladder Cancer+8 more
IRCCS San Raffaele20,000 enrolled1 locationNCT06167356